FDA Inspection 1172085 — ImpactLife
The FDA completed an inspection of ImpactLife on May 18, 2022 in Ottumwa, IA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 18, 2022
- Fiscal Year
- 2022
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Ottumwa, IA (United States)